Israel-based Foamix has developed a number of applications for its proprietary foam technologies, which include the delivery of both active ingredients for cosmetic products as well medical and pharmaceutical products. Denmark-based Leo says that the agreement includes significant milestone payments to Foamix upon the attainment of development, regulatory and clinical goals. Foamix will be responsible for the foam formulation development of the two products. Likewise, Leo says that it will be responsible for the clinical and regulatory development as well as sales and marketing of the products in the agreed territories. "We believe that Foamix foam offers the perfect properties to deliver our anti-psoriasis actives. It spreads easily over large surfaces, absorbs instantly, doesn't burn and can deliver the active agents necessary to effectively treat psoriasis," said Ernst Lunding, Leo CEO.